Catch Bio key facts
as of Oct 2026- Developer of a preventive health platform designed to help people understand and lower their risk of cancer.
- Catch Bio is valued at approximately $60.0M as of Oct 2026 (last reported valuation).
- It has raised $40.8M; the latest was Early Stage VC ($750K) in Mar 2026.
- Notable investors include Spacestation (UK), DML Group, Grt Sht Ventures, Hannah Grey Ventures, Wild Ventures.
- Status: Privately Held (backing).
Catch Bio's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch Catch Bio: the Monday email on marks, rounds and moves
Catch Bio funding rounds
No funding rounds for Catch Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Catch Bio
5Catch Bio valuation
Catch Bio's last reported valuation was $60 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Catch Bio investors
5 investors are on record for Catch Bio, including Spacestation (UK), DML Group, Grt Sht Ventures and Hannah Grey Ventures.
About Catch Bio
Developer of a preventive health platform designed to help people understand and lower their risk of cancer. The company offers risk assessments based on validated health factors, biomarker analysis, and personalized action plans, enabling individuals concerned about long-term cancer risk to make informed lifestyle and screening decisions.
- Sector
- Healthcare
- HQ
- Lewes, DE, United States
- Founded
- 2023
- Website
- catchbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.